[Treatment of Posterior Noninfectious Uveitis : Current Situation and Future Developments]

Overview

Journal Ophthalmologe

Specialty Ophthalmology

Date 2016 May 12

PMID 27165275

Citations 3

Authors

U Pleyer

D Pohlmann

N Stubiger

Affiliations

Soon will be listed here.

Abstract

Treatment of autoimmune diseases has undergone significant changes and developments in recent years. New classes of active substances, in particular biologics and small molecules have resulted in previously unknown success in the treatment of many diseases. In particular patients suffering from autoimmune rheumatic or dermatological diseases have benefited. For autoimmune uveitis there are numerous reports indicating excellent therapeutic and preventive effects; however, statutory approval for therapy in adults is still pending. This article outlines recent advances and future therapeutic options for the treatment of posterior segment noninfectious uveitis.

Citing Articles

[Noninfectious posterior uveitis : Clinical aspects, diagnostics, management and treatment].

Pohlmann D, Zur Bonsen L, Rubsam A, Pleyer U Ophthalmologie. 2023; 120(4):443-458.

PMID: 37022476 DOI: 10.1007/s00347-023-01833-5.

[DOG and BVA guideline no. 24b : Noninfectious uveitis posterior].

Ophthalmologe. 2017; 114(12):1122-1134.

PMID: 29159575 DOI: 10.1007/s00347-017-0582-z.

[Optimization of therapy of autoimmune diseases of the eye : Novel approaches].

Pleyer U Ophthalmologe. 2016; 113(5):370-2.

PMID: 27154026 DOI: 10.1007/s00347-016-0266-0.

References

Kempen J, Daniel E, Gangaputra S, Dreger K, Jabs D, Kacmaz R . Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol. 2008; 15(1):47-55. DOI: 10.1080/09286580701585892. View

Lopalco G, Cantarini L, Vitale A, Iannone F, Anelli M, Andreozzi L . Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediators Inflamm. 2015; 2015:194864. PMC: 4345261. DOI: 10.1155/2015/194864. View

Jabs D, Rosenbaum J, Foster C, Holland G, Jaffe G, Louie J . Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000; 130(4):492-513. DOI: 10.1016/s0002-9394(00)00659-0. View

Smet M, Taylor S, Bodaghi B, Miserocchi E, Murray P, Pleyer U . Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res. 2011; 30(6):452-70. DOI: 10.1016/j.preteyeres.2011.06.005. View

Yoshimura T, Sonoda K, Ohguro N, Ohsugi Y, Ishibashi T, Cua D . Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford). 2009; 48(4):347-54. PMC: 2722800. DOI: 10.1093/rheumatology/ken489. View

Gul A, Tugal-Tutkun I, Dinarello C, Reznikov L, Esen B, Mirza A . Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann Rheum Dis. 2011; 71(4):563-6. DOI: 10.1136/annrheumdis-2011-155143. View

Stubiger N, Winterhalter S, Pleyer U, Doycheva D, Zierhut M, Deuter C . [Janus-faced?: Effects and side-effects of interferon therapy in ophthalmology]. Ophthalmologe. 2011; 108(3):204-12. DOI: 10.1007/s00347-010-2261-1. View

Kurose S, Ikeda E, Tokiwa M, Hikita N, Mochizuki M . Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats. Exp Eye Res. 2000; 70(1):7-15. DOI: 10.1006/exer.1999.0777. View

Tsambaos D, Eichelberg D, Goos M . Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res. 1986; 278(4):335-6. DOI: 10.1007/BF00407749. View

10.

Hazirolan D, Pleyer U . Think global--act local: intravitreal drug delivery systems in chronic noninfectious uveitis. Ophthalmic Res. 2012; 49(2):59-65. DOI: 10.1159/000345477. View

11.

Tappeiner C, Heinz C, Ganser G, Heiligenhaus A . Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?. J Rheumatol. 2012; 39(6):1294-5. DOI: 10.3899/jrheum.120010. View

12.

Servat J, Mears K, Black E, Huang J . Biological agents for the treatment of uveitis. Expert Opin Biol Ther. 2012; 12(3):311-28. DOI: 10.1517/14712598.2012.658366. View

13.

Johnsson H, McInnes I . Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis. Clin Exp Rheumatol. 2015; 33(5 Suppl 93):S115-8. View

14.

Huang J, Yafawi R, Zhang M, McDowell M, Rittenhouse K, Sace F . Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease. Ophthalmology. 2012; 119(7):e43-50. DOI: 10.1016/j.ophtha.2012.03.017. View

15.

Miserocchi E, Modorati G, Berchicci L, Pontikaki I, Meroni P, Gerloni V . Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol. 2015; 100(6):782-6. DOI: 10.1136/bjophthalmol-2015-306790. View

16.

Adan A, Mesquida M, Llorenc V, Espinosa G, Molins B, Hernandez M . Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013; 251(11):2627-32. DOI: 10.1007/s00417-013-2436-y. View

17.

Horai R, Caspi R . Cytokines in autoimmune uveitis. J Interferon Cytokine Res. 2011; 31(10):733-44. PMC: 3189550. DOI: 10.1089/jir.2011.0042. View

18.

Copland D, Liu J, Schewitz-Bowers L, Brinkmann V, Anderson K, Nicholson L . Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier. Am J Pathol. 2011; 180(2):672-81. PMC: 3796282. DOI: 10.1016/j.ajpath.2011.10.008. View

19.

Maiz Alonso O, Blanco Esteban A, Egues Dubuc C, Martinez Zabalegui D . Effectiveness of certolizumab pegol in chronic anterior uveitis associated to Crohn's disease and ankylosing spondylitis. Reumatol Clin. 2015; 11(3):189-90. DOI: 10.1016/j.reuma.2014.10.006. View

20.

Borras-Blasco J, Castera D, Cortes X, Abad F, Rosique-Robles J, Mallench L . Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults. Int J Clin Pharmacol Ther. 2014; 53(5):377-90. DOI: 10.5414/CP202171. View